Theravance Biopharma Stock Forecast

Stock Price Forecast

The 4 analysts with 12-month price forecasts for Theravance Biopharma stock have an average target of 13.75, with a low estimate of 9.00 and a high estimate of 21. The average target predicts an increase of 48.97% from the current stock price of 9.23.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$9.00	$13.75	$15	$21
Change	-2.49%	+48.97%	+62.51%	+127.52%

* Price targets were last updated on Feb 27, 2025.

Analyst Ratings

The average analyst rating for Theravance Biopharma stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $15	Strong Buy	Reiterates	$15	+62.51%	Feb 27, 2025
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $15	Strong Buy	Reiterates	$15	+62.51%	Feb 25, 2025
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $15	Strong Buy	Reiterates	$15	+62.51%	Sep 16, 2024
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $20 → $15	Strong Buy	Maintains	$20 → $15	+62.51%	Aug 6, 2024
Marc Frahm TD Cowen	TD Cowen	Hold Maintains $10 → $9	Hold	Maintains	$10 → $9	-2.49%	Aug 6, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

89.71M

from 64.38M

39.34%

from 64.38M

Revenue Next Year

92.97M

from 89.71M

3.63%

from 89.71M

EPS This Year

-0.34

from -1.15

EPS Next Year

-1.03

from -0.34

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	71.86M	55.31M	51.35M	57.42M	64.38M	89.71M	92.97M	107.05M
Revenue Growth	-2.12%	-23.03%	-7.17%	11.84%	12.12%	39.34%	3.63%	15.14%
EPS	-4.46	-2.87	11.85	-1.00	-1.15	-0.34	-1.03	-0.59
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	6	6	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	98.9M	113.1M	129.9M
Avg	89.7M	93.0M	107.1M
Low	75.2M	69.0M	77.6M

Revenue Growth

Revenue Growth	2025	2026	2027
High	53.6%	26.1%	39.7%
Avg	39.3%	3.6%	15.1%
Low	16.8%	-23.1%	-16.5%

EPS Forecast

EPS	2025	2026	2027
High	-0.22	-0.86	-0.23
Avg	-0.34	-1.03	-0.59
Low	-0.48	-1.31	-0.74

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.